Multi-Center Registry Trial of Bivalirudin for Chinese Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800016751

Enrollment

Unknown

Registered

2018-06-21

Start date

2018-06-05

Completion date

Unknown

Last updated

2018-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Interventions

Case series:Bivalirudin, in combination with antiplatelet agents such as aspirin, P2Y12 inhibitors, and glycoprotein IIb/IIIa inhibitors

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Clinical diagnosis of coronary heart disease; 2. PCI was planned and Bivalirudin (Salubris Pharmaceuticals Co) was planned during the PCI procedure; 3. receiving standard antiplatelet agents during PCI; 4. signed informed written consent.

Exclusion criteria

Exclusion criteria: 1. unsuitable for acception of PCI or Bivalirudin; 2. Patient unwilling or unable to provide written informed consent.

Design outcomes

Primary

Measure	Time frame
???????;	—

Countries

China

Contacts

Public ContactLikun Ma

The First Affiliated Hospital of USTC (Anhui Provincial Hospital)

lkma119@163.com+86 18756967633

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026